vs
Finward Bancorp（FNWD）与Xtant Medical Holdings, Inc.（XTNT）财务数据对比。点击上方公司名可切换其他公司
Xtant Medical Holdings, Inc.的季度营收约是Finward Bancorp的2.0倍（$32.4M vs $16.5M），Finward Bancorp净利率更高（12.0% vs 0.2%，领先11.8%），Xtant Medical Holdings, Inc.同比增速更快（2.7% vs 1.1%），Finward Bancorp自由现金流更多（$9.0M vs $5.0M），过去两年Xtant Medical Holdings, Inc.的营收复合增速更高（7.7% vs -19.1%）
Finward Bancorp是一家总部位于美国的区域性银行控股公司，主要面向本土运营区域内的个人消费者与中小企业，提供储蓄账户、各类贷款、商业融资及财富管理等零售与商业金融服务。
Xtant Medical Holdings是一家全球医疗技术企业，主营骨科生物制剂、神经外科器械及再生医学解决方案，为骨科与神经科诊疗机构提供脊柱手术耗材、骨再生产品等，服务覆盖北美、欧洲及亚太多个地区市场。
FNWD vs XTNT — 直观对比
营收规模更大
XTNT
是对方的2.0倍
$16.5M
营收增速更快
XTNT
高出1.6%
1.1%
净利率更高
FNWD
高出11.8%
0.2%
自由现金流更多
FNWD
多$4.1M
$5.0M
两年增速更快
XTNT
近两年复合增速
-19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.5M | $32.4M |
| 净利润 | $2.0M | $57.0K |
| 毛利率 | — | 54.9% |
| 营业利润率 | 11.0% | -2.9% |
| 净利率 | 12.0% | 0.2% |
| 营收同比 | 1.1% | 2.7% |
| 净利润同比 | -5.6% | 101.8% |
| 每股收益（稀释后） | $0.46 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNWDXTNT
| Q4 25 | $16.5M | $32.4M | ||
| Q3 25 | $17.4M | $33.3M | ||
| Q2 25 | $16.6M | $35.4M | ||
| Q1 25 | $15.5M | $32.9M | ||
| Q4 24 | $16.3M | $31.5M | ||
| Q3 24 | $14.9M | $27.9M | ||
| Q2 24 | $14.6M | $29.9M | ||
| Q1 24 | $25.3M | $27.9M |
净利润FNWDXTNT
| Q4 25 | $2.0M | $57.0K | ||
| Q3 25 | $3.5M | $1.3M | ||
| Q2 25 | $2.2M | $3.5M | ||
| Q1 25 | $455.0K | $58.0K | ||
| Q4 24 | $2.1M | $-3.2M | ||
| Q3 24 | $606.0K | $-5.0M | ||
| Q2 24 | $143.0K | $-3.9M | ||
| Q1 24 | $9.3M | $-4.4M |
毛利率FNWDXTNT
| Q4 25 | — | 54.9% | ||
| Q3 25 | — | 66.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 50.9% | ||
| Q3 24 | — | 58.4% | ||
| Q2 24 | — | 62.1% | ||
| Q1 24 | — | 62.1% |
营业利润率FNWDXTNT
| Q4 25 | 11.0% | -2.9% | ||
| Q3 25 | 20.5% | 7.6% | ||
| Q2 25 | 12.7% | 13.1% | ||
| Q1 25 | 4.0% | 3.2% | ||
| Q4 24 | 16.3% | -6.0% | ||
| Q3 24 | 2.7% | -13.5% | ||
| Q2 24 | 0.9% | -9.8% | ||
| Q1 24 | 40.6% | -12.4% |
净利率FNWDXTNT
| Q4 25 | 12.0% | 0.2% | ||
| Q3 25 | 20.1% | 3.9% | ||
| Q2 25 | 12.9% | 10.0% | ||
| Q1 25 | 2.9% | 0.2% | ||
| Q4 24 | 12.9% | -10.0% | ||
| Q3 24 | 4.1% | -18.0% | ||
| Q2 24 | 1.0% | -12.9% | ||
| Q1 24 | 36.7% | -15.8% |
每股收益（稀释后）FNWDXTNT
| Q4 25 | $0.46 | $0.00 | ||
| Q3 25 | $0.81 | $0.01 | ||
| Q2 25 | $0.50 | $0.02 | ||
| Q1 25 | $0.11 | $0.00 | ||
| Q4 24 | $0.50 | $-0.02 | ||
| Q3 24 | $0.14 | $-0.04 | ||
| Q2 24 | $0.03 | $-0.03 | ||
| Q1 24 | $2.17 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $17.1M |
| 总债务越低越好 | — | $11.0M |
| 股东权益账面价值 | $174.7M | $51.0M |
| 总资产 | $2.0B | $94.1M |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资FNWDXTNT
| Q4 25 | — | $17.1M | ||
| Q3 25 | — | $10.4M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $5.0M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | — | $5.4M | ||
| Q1 24 | — | $4.5M |
总债务FNWDXTNT
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $16.8M |
股东权益FNWDXTNT
| Q4 25 | $174.7M | $51.0M | ||
| Q3 25 | $165.5M | $50.4M | ||
| Q2 25 | $154.3M | $48.5M | ||
| Q1 25 | $151.8M | $43.9M | ||
| Q4 24 | $151.4M | $43.0M | ||
| Q3 24 | $159.6M | $45.7M | ||
| Q2 24 | $148.6M | $45.0M | ||
| Q1 24 | $151.6M | $47.7M |
总资产FNWDXTNT
| Q4 25 | $2.0B | $94.1M | ||
| Q3 25 | $2.1B | $106.3M | ||
| Q2 25 | $2.1B | $103.5M | ||
| Q1 25 | $2.0B | $95.8M | ||
| Q4 24 | $2.1B | $93.8M | ||
| Q3 24 | $2.1B | $98.9M | ||
| Q2 24 | $2.1B | $95.6M | ||
| Q1 24 | $2.1B | $93.9M |
负债/权益比FNWDXTNT
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | $9.0M | $5.0M |
| 自由现金流率自由现金流/营收 | 54.8% | 15.4% |
| 资本支出强度资本支出/营收 | 5.2% | 1.2% |
| 现金转化率经营现金流/净利润 | 4.99× | 94.39× |
| 过去12个月自由现金流最近4个季度 | $10.6M | $10.2M |
8季度趋势，按日历期对齐
经营现金流FNWDXTNT
| Q4 25 | $9.9M | $5.4M | ||
| Q3 25 | $1.2M | $4.6M | ||
| Q2 25 | $4.8M | $1.3M | ||
| Q1 25 | $-3.8M | $1.3M | ||
| Q4 24 | $9.8M | $665.0K | ||
| Q3 24 | $-3.7M | $-1.7M | ||
| Q2 24 | $2.8M | $-5.1M | ||
| Q1 24 | $-25.0K | $-5.8M |
自由现金流FNWDXTNT
| Q4 25 | $9.0M | $5.0M | ||
| Q3 25 | $1.0M | $4.2M | ||
| Q2 25 | $4.5M | $910.0K | ||
| Q1 25 | $-4.0M | $87.0K | ||
| Q4 24 | $6.7M | $-7.0K | ||
| Q3 24 | $-4.2M | $-3.8M | ||
| Q2 24 | $1.1M | $-5.7M | ||
| Q1 24 | $-736.0K | $-6.5M |
自由现金流率FNWDXTNT
| Q4 25 | 54.8% | 15.4% | ||
| Q3 25 | 6.0% | 12.6% | ||
| Q2 25 | 27.0% | 2.6% | ||
| Q1 25 | -25.7% | 0.3% | ||
| Q4 24 | 41.2% | -0.0% | ||
| Q3 24 | -28.5% | -13.7% | ||
| Q2 24 | 7.6% | -18.9% | ||
| Q1 24 | -2.9% | -23.4% |
资本支出强度FNWDXTNT
| Q4 25 | 5.2% | 1.2% | ||
| Q3 25 | 0.9% | 1.3% | ||
| Q2 25 | 1.7% | 1.0% | ||
| Q1 25 | 1.2% | 3.6% | ||
| Q4 24 | 18.8% | 2.1% | ||
| Q3 24 | 3.4% | 7.5% | ||
| Q2 24 | 11.2% | 1.9% | ||
| Q1 24 | 2.8% | 2.8% |
现金转化率FNWDXTNT
| Q4 25 | 4.99× | 94.39× | ||
| Q3 25 | 0.34× | 3.53× | ||
| Q2 25 | 2.22× | 0.36× | ||
| Q1 25 | -8.37× | 22.03× | ||
| Q4 24 | 4.66× | — | ||
| Q3 24 | -6.15× | — | ||
| Q2 24 | 19.23× | — | ||
| Q1 24 | -0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNWD
暂无分部数据
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
